Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.

Abstract	Combination chemotherapy with gemcitabine (Gem), doxorubicin (Dox), and paclitaxel (Pac) (GAT) has been considered attractive as first-line treatment in metastatic breast cancer. We compared the potential of various schedules of GAT to induce apoptosis on MDA-MB-231, MCF7, and T47D human breast cancer cell lines. The extent of apoptotic induction was analyzed by flow cytometry with 7-aminoactinomycin D (7AAD) staining. Differences between various schedules in terms of apoptotic induction were statistically significant (P < 0.05). The most effective apoptotic induction regimen was achieved by the sequence: Dox for 16 h followed by Pac + Gem. Schedules employing a 16-h interval between drug administrations induced higher levels of apoptosis in human breast cancer cell lines compared with schedules using a 4-h interval. The therapeutic efficacy of the experimental results shown in this paper has been clinically corroborated in a phase II trial in metastatic breast cancer patients.
Authors	Maria J Serrano, Pedro Sánchez-Rovira, Ignacio Algarra, Ana Jaén, Ana Lozano, José J Gaforio
Journal	Japanese journal of cancer research : Gann (Jpn J Cancer Res) Vol. 93 Issue 5 Pg. 559-66 (May 2002) ISSN: 0910-5050 [Print] Japan
PMID	12036452 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antibiotics, Antineoplastic Deoxycytidine Dactinomycin Doxorubicin Paclitaxel Gemcitabine
Topics	Antibiotics, Antineoplastic (pharmacology) Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Apoptosis Breast Neoplasms (metabolism, pathology) Cell Division Cell Survival Clinical Trials as Topic Dactinomycin (pharmacology) Deoxycytidine (administration & dosage, analogs & derivatives) Dose-Response Relationship, Drug Doxorubicin (administration & dosage) Flow Cytometry Humans Paclitaxel (administration & dosage) Time Factors Tumor Cells, Cultured Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!